TNF and lymphoma: In one study using meta-analysis, the standardized incidence ration of lymphoma in IBD patients treated by anti-TNF was estimated to be 1.7 as compared to patients treated by immunomodulation only.76 However, in a cohort of 6273 CD patients treated by infliximab and followed for 5 years no increased risk for lymphoma was noted.